Home > Events > Raps us convergence 2025

1 min read

RAPS US Convergence

Meet Veristat at RAPS US Convergence 2025 

Where Regulatory Excellence Meets Real-World Impact 

Veristat is delighted to participate in RAPS US Convergence 2025, the leading regulatory affairs conference in North America. The event will be held October 7–9, 2025, at the David L. Lawrence Convention Center in Pittsburgh, PA.

This premier conference brings together global experts to explore the latest trends and challenges in healthcare regulation, with focused sessions on devices, IVDs, pharmaceuticals, AI, software, and more.

Visit Us at Booth #310

As a leading global clinical research organization (CRO) and consultancy, discover how Veristat blends deep scientific knowledge with strategic regulatory insight to guide sponsors through every stage of clinical development. Whether you're:

  • Building a regulatory strategy

  • Preparing for agency meetings

  • Advancing to pivotal Phase 3 trials

  • Planning a global marketing submission

With 190+ marketing applications and 180+ INDs/CTAs prepared in past 5 years, Veristat is at the forefront of regulatory excellence. Meet us at RAPS US Convergence 2025 to see how our experience and flexibility can help accelerate your path to approval.

Veristat Attendees

  • Alison Bawden - Senior Director, Regulatory Affairs

  • Victor Zevallos - Senior Business Development Director

  • Mandy McCormick - Business Development Manager

Conference Details

As a leading global clinical research organization (CRO) and consultancy, discover how Veristat blends deep scientific knowledge with strategic regulatory insight to guide sponsors through every stage of clinical development. Whether you're:

  • Event: RAPS US Convergence 2025

  • Dates: October 7-9, 2025

  • Booth number: 310

  • Location: David L. Lawrence Convention Center, Pittsburgh, Pennsylvania


Schedule a Meeting

Let’s connect! Meet with our regulatory experts to explore how Veristat can help you navigate global regulatory pathways and bring your therapies to market faster.

 

Share This Event:

   

4 min read

ASCO 2026: RAS Is No Longer Undruggable

For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes...

10 min read

Monthly FDA Guidance and Regulatory News Review - May 2026

This May 2026 regulatory update highlights multiple guidances issued by the FDA across cell and gene therapy, clinical...